Development and characterization of a novel mab against bilitranslocase - A new biomarker of renal carcinoma

Sendi Montanic, Michela Terdoslavich, Uros Rajcevic, Luigina De Leo, Serena Bonin, Vladka Curin Serbec, Sabina Passamonti

Research output: Contribution to journalArticle

Abstract

Background. Bilitranslocase (TC 2.A.65.1.1) is a bilirubin-specific membrane transporter, found on absorptive (stomach and intestine) and excretory (kidney and liver) epithelia and in vascular endothelium. Polyclonal antibodies have been raised in rabbits in the past, using a synthetic peptide corresponding to AA65-77 of rat liver bilitranslocase, as an antigen. Affinity-purified antibodies from immune sera have been found to inhibit various membrane transport functions, including the bilirubin uptake into human hepatocytes and the uptake of some flavonoids into human vascular endothelial cells. It was described by means of immunohistochemistry using polyclonal antibodies that bilitranslocase expression is severely down-regulated in clear cell renal carcinoma. The aim of our work was development and characterization of high-affinity, specific mAbs against bilitranslocase, which can be used as a potential diagnostic tool in renal cell carcinoma as well as in a wide variety of biological assays on different human tissues. Materials and methods. Mice were immunized with a multi-antigen peptide corresponding to segment 65-75 of predicted primary structure of the bilitranslocase protein. By a sequence of cloning, immune- And functional tests, we aimed at obtaining a specific monoclonal antibody which recognizes a 37 kDa membrane protein, and influences the transport activity of bilitranslocase. Results. On the basis of previous results, specific IgM monoclonal antibodies were produced in BALB/c mice, in order to further improve and extend the immunological approach to the study of bilitranslocase in renal cancer cells as well as to develop its potential diagnostics use. Conclusions. In this article we show an immunological approach, based on newly developed monoclonal antibodies, to a detailed biochemical and functional characterization of a protein whose gene and protein structure is still unknown. We were able to demonstrate our novel mAb as a tumor marker candidate of renal cell carcinoma, which may prove useful in the diagnostic procedures.

Original languageEnglish
Pages (from-to)128-137
Number of pages10
JournalRadiology and Oncology
Volume47
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

Biomarkers
Carcinoma
Kidney
Renal Cell Carcinoma
Membrane Transport Proteins
Monoclonal Antibodies
Bilirubin
Antigens
Peptides
Antibody Affinity
Antibodies
Liver
Vascular Endothelium
Tumor Biomarkers
bilitranslocase
Flavonoids
Biological Assay
Intestines
Immunoglobulin M
Organism Cloning

Keywords

  • Bilitranslocase
  • Kidney
  • Monoclonal antibody
  • Peptide antigen
  • Renal cell carcinoma
  • Tumor marker

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Montanic, S., Terdoslavich, M., Rajcevic, U., Leo, L. D., Bonin, S., Serbec, V. C., & Passamonti, S. (2013). Development and characterization of a novel mab against bilitranslocase - A new biomarker of renal carcinoma. Radiology and Oncology, 47(2), 128-137. https://doi.org/10.2478/raon-2013-0026

Development and characterization of a novel mab against bilitranslocase - A new biomarker of renal carcinoma. / Montanic, Sendi; Terdoslavich, Michela; Rajcevic, Uros; Leo, Luigina De; Bonin, Serena; Serbec, Vladka Curin; Passamonti, Sabina.

In: Radiology and Oncology, Vol. 47, No. 2, 2013, p. 128-137.

Research output: Contribution to journalArticle

Montanic, S, Terdoslavich, M, Rajcevic, U, Leo, LD, Bonin, S, Serbec, VC & Passamonti, S 2013, 'Development and characterization of a novel mab against bilitranslocase - A new biomarker of renal carcinoma', Radiology and Oncology, vol. 47, no. 2, pp. 128-137. https://doi.org/10.2478/raon-2013-0026
Montanic, Sendi ; Terdoslavich, Michela ; Rajcevic, Uros ; Leo, Luigina De ; Bonin, Serena ; Serbec, Vladka Curin ; Passamonti, Sabina. / Development and characterization of a novel mab against bilitranslocase - A new biomarker of renal carcinoma. In: Radiology and Oncology. 2013 ; Vol. 47, No. 2. pp. 128-137.
@article{bac8fcfe8a18456bb9443bc306f4a661,
title = "Development and characterization of a novel mab against bilitranslocase - A new biomarker of renal carcinoma",
abstract = "Background. Bilitranslocase (TC 2.A.65.1.1) is a bilirubin-specific membrane transporter, found on absorptive (stomach and intestine) and excretory (kidney and liver) epithelia and in vascular endothelium. Polyclonal antibodies have been raised in rabbits in the past, using a synthetic peptide corresponding to AA65-77 of rat liver bilitranslocase, as an antigen. Affinity-purified antibodies from immune sera have been found to inhibit various membrane transport functions, including the bilirubin uptake into human hepatocytes and the uptake of some flavonoids into human vascular endothelial cells. It was described by means of immunohistochemistry using polyclonal antibodies that bilitranslocase expression is severely down-regulated in clear cell renal carcinoma. The aim of our work was development and characterization of high-affinity, specific mAbs against bilitranslocase, which can be used as a potential diagnostic tool in renal cell carcinoma as well as in a wide variety of biological assays on different human tissues. Materials and methods. Mice were immunized with a multi-antigen peptide corresponding to segment 65-75 of predicted primary structure of the bilitranslocase protein. By a sequence of cloning, immune- And functional tests, we aimed at obtaining a specific monoclonal antibody which recognizes a 37 kDa membrane protein, and influences the transport activity of bilitranslocase. Results. On the basis of previous results, specific IgM monoclonal antibodies were produced in BALB/c mice, in order to further improve and extend the immunological approach to the study of bilitranslocase in renal cancer cells as well as to develop its potential diagnostics use. Conclusions. In this article we show an immunological approach, based on newly developed monoclonal antibodies, to a detailed biochemical and functional characterization of a protein whose gene and protein structure is still unknown. We were able to demonstrate our novel mAb as a tumor marker candidate of renal cell carcinoma, which may prove useful in the diagnostic procedures.",
keywords = "Bilitranslocase, Kidney, Monoclonal antibody, Peptide antigen, Renal cell carcinoma, Tumor marker",
author = "Sendi Montanic and Michela Terdoslavich and Uros Rajcevic and Leo, {Luigina De} and Serena Bonin and Serbec, {Vladka Curin} and Sabina Passamonti",
year = "2013",
doi = "10.2478/raon-2013-0026",
language = "English",
volume = "47",
pages = "128--137",
journal = "Radiology and Oncology",
issn = "1318-2099",
publisher = "Slovenian Medical Society / Croatian Medical Association",
number = "2",

}

TY - JOUR

T1 - Development and characterization of a novel mab against bilitranslocase - A new biomarker of renal carcinoma

AU - Montanic, Sendi

AU - Terdoslavich, Michela

AU - Rajcevic, Uros

AU - Leo, Luigina De

AU - Bonin, Serena

AU - Serbec, Vladka Curin

AU - Passamonti, Sabina

PY - 2013

Y1 - 2013

N2 - Background. Bilitranslocase (TC 2.A.65.1.1) is a bilirubin-specific membrane transporter, found on absorptive (stomach and intestine) and excretory (kidney and liver) epithelia and in vascular endothelium. Polyclonal antibodies have been raised in rabbits in the past, using a synthetic peptide corresponding to AA65-77 of rat liver bilitranslocase, as an antigen. Affinity-purified antibodies from immune sera have been found to inhibit various membrane transport functions, including the bilirubin uptake into human hepatocytes and the uptake of some flavonoids into human vascular endothelial cells. It was described by means of immunohistochemistry using polyclonal antibodies that bilitranslocase expression is severely down-regulated in clear cell renal carcinoma. The aim of our work was development and characterization of high-affinity, specific mAbs against bilitranslocase, which can be used as a potential diagnostic tool in renal cell carcinoma as well as in a wide variety of biological assays on different human tissues. Materials and methods. Mice were immunized with a multi-antigen peptide corresponding to segment 65-75 of predicted primary structure of the bilitranslocase protein. By a sequence of cloning, immune- And functional tests, we aimed at obtaining a specific monoclonal antibody which recognizes a 37 kDa membrane protein, and influences the transport activity of bilitranslocase. Results. On the basis of previous results, specific IgM monoclonal antibodies were produced in BALB/c mice, in order to further improve and extend the immunological approach to the study of bilitranslocase in renal cancer cells as well as to develop its potential diagnostics use. Conclusions. In this article we show an immunological approach, based on newly developed monoclonal antibodies, to a detailed biochemical and functional characterization of a protein whose gene and protein structure is still unknown. We were able to demonstrate our novel mAb as a tumor marker candidate of renal cell carcinoma, which may prove useful in the diagnostic procedures.

AB - Background. Bilitranslocase (TC 2.A.65.1.1) is a bilirubin-specific membrane transporter, found on absorptive (stomach and intestine) and excretory (kidney and liver) epithelia and in vascular endothelium. Polyclonal antibodies have been raised in rabbits in the past, using a synthetic peptide corresponding to AA65-77 of rat liver bilitranslocase, as an antigen. Affinity-purified antibodies from immune sera have been found to inhibit various membrane transport functions, including the bilirubin uptake into human hepatocytes and the uptake of some flavonoids into human vascular endothelial cells. It was described by means of immunohistochemistry using polyclonal antibodies that bilitranslocase expression is severely down-regulated in clear cell renal carcinoma. The aim of our work was development and characterization of high-affinity, specific mAbs against bilitranslocase, which can be used as a potential diagnostic tool in renal cell carcinoma as well as in a wide variety of biological assays on different human tissues. Materials and methods. Mice were immunized with a multi-antigen peptide corresponding to segment 65-75 of predicted primary structure of the bilitranslocase protein. By a sequence of cloning, immune- And functional tests, we aimed at obtaining a specific monoclonal antibody which recognizes a 37 kDa membrane protein, and influences the transport activity of bilitranslocase. Results. On the basis of previous results, specific IgM monoclonal antibodies were produced in BALB/c mice, in order to further improve and extend the immunological approach to the study of bilitranslocase in renal cancer cells as well as to develop its potential diagnostics use. Conclusions. In this article we show an immunological approach, based on newly developed monoclonal antibodies, to a detailed biochemical and functional characterization of a protein whose gene and protein structure is still unknown. We were able to demonstrate our novel mAb as a tumor marker candidate of renal cell carcinoma, which may prove useful in the diagnostic procedures.

KW - Bilitranslocase

KW - Kidney

KW - Monoclonal antibody

KW - Peptide antigen

KW - Renal cell carcinoma

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=84884993639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884993639&partnerID=8YFLogxK

U2 - 10.2478/raon-2013-0026

DO - 10.2478/raon-2013-0026

M3 - Article

C2 - 23801909

AN - SCOPUS:84884993639

VL - 47

SP - 128

EP - 137

JO - Radiology and Oncology

JF - Radiology and Oncology

SN - 1318-2099

IS - 2

ER -